Paris: France is preparing to make costly weight loss medicines available through its public healthcare system in a move that could change the way obesity is treated across Europe. The French government announced that from mid June, some patients suffering from severe obesity will be able to receive reimbursement for medicines such as Wegovy and Mounjaro under the national health insurance program.
French Health Minister Stéphanie Rist said the decision was taken because obesity is becoming a growing public health concern in the country. Officials believe helping patients gain access to treatment earlier could reduce future cases of diabetes, heart disease and other serious illnesses linked to obesity.
For many patients struggling with severe weight problems, the announcement has brought hope. Obesity affects millions of people in France, and many families have found it difficult to afford modern treatments because of their high prices. Some of the medicines can cost hundreds of euros every month, placing them out of reach for ordinary people.
The medicines involved belong to a group of drugs known as GLP 1 treatments. Originally developed for diabetes, the drugs became internationally famous after studies showed that many patients lost significant amounts of weight while taking them. They work by helping people feel full for longer periods and by reducing appetite.
Over the past two years, these medicines have transformed conversations about obesity around the world. Many doctors now describe obesity as a long term medical condition rather than simply the result of poor lifestyle choices. Health experts say this change in understanding is important because many patients have spent years facing stigma and blame while struggling with weight related health problems.
France’s decision is being closely watched by other European countries. Several governments across Europe have been hesitant to fully reimburse the drugs because of concerns about rising healthcare costs. In some countries, obesity medicines are still considered lifestyle treatments instead of essential medical care.
Medical experts say the French policy could influence future healthcare decisions in other nations if the program proves successful. Some researchers believe investing in obesity treatment today could lower future spending on chronic illnesses and hospital care.
At the same time, concerns remain about the financial pressure these medicines could place on public healthcare systems. Since demand for the drugs has grown rapidly worldwide, some governments worry that large scale reimbursement programs may become too expensive in the long term.
Doctors have also warned that patients may need to continue treatment for years in order to maintain weight loss. Recent studies showed that many people regained weight after stopping the medicines, raising questions about whether obesity treatment may become a lifelong process for some patients.
Despite these concerns, many patient groups welcomed the French government’s announcement. Advocacy organizations said the decision recognizes the emotional and physical struggles faced by people living with severe obesity.
The French government has indicated that reimbursement will mainly target patients with serious obesity related health risks rather than people seeking weight loss for cosmetic reasons. Health authorities are expected to release more details in the coming weeks about eligibility rules and how patients can access the treatments.
The decision marks an important moment in Europe’s healthcare debate, as governments increasingly face pressure to respond to rising obesity rates while balancing public health budgets. For many patients in France, however, the announcement represents something more personal: a chance to receive treatment that was previously beyond their financial reach.